21.97
전일 마감가:
$20.85
열려 있는:
$20.91
하루 거래량:
1.80M
Relative Volume:
1.80
시가총액:
$1.26B
수익:
$2.28B
순이익/손실:
$-1.13B
주가수익비율:
-1.1062
EPS:
-19.86
순현금흐름:
$35.92M
1주 성능:
+4.02%
1개월 성능:
-12.99%
6개월 성능:
-19.58%
1년 성능:
-28.34%
Enovis Corp Stock (ENOV) Company Profile
명칭
Enovis Corp
전화
(302) 252-9160
주소
2711 CENTERVILLE ROAD, WILMINGTON
Compare ENOV vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ENOV
Enovis Corp
|
21.97 | 1.26B | 2.28B | -1.13B | 35.92M | -19.86 |
|
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
|
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Enovis Corp Stock (ENOV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 재개 | William Blair | Outperform |
| 2026-01-06 | 개시 | BTIG Research | Buy |
| 2024-10-03 | 개시 | JMP Securities | Mkt Outperform |
| 2024-06-13 | 개시 | JP Morgan | Neutral |
| 2024-02-13 | 개시 | Stephens | Overweight |
| 2024-01-22 | 개시 | UBS | Buy |
| 2024-01-03 | 개시 | William Blair | Outperform |
| 2023-12-15 | 재확인 | Needham | Buy |
| 2023-10-20 | 개시 | ROTH MKM | Buy |
| 2023-06-26 | 개시 | Needham | Buy |
| 2023-05-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-10-11 | 개시 | Goldman | Buy |
| 2022-09-12 | 개시 | Canaccord Genuity | Buy |
| 2022-09-12 | 개시 | Evercore ISI | Outperform |
| 2022-06-28 | 개시 | Argus | Hold |
| 2022-06-27 | 재개 | Loop Capital | Buy |
| 2022-06-16 | 개시 | Wells Fargo | Equal Weight |
모두보기
Enovis Corp 주식(ENOV)의 최신 뉴스
Enovis Corp (ENOV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Enovis Corp (ENOV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Enovis Corp (ENOV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enovis (ENOV) Stock Could Be 49.8% Undervalued After Spinamic Brace Launch - simplywall.st
Insider Buying: Oliver Engert Acquires Additional Shares of Enovis Corp (ENOV) - GuruFocus
Enovis chief administrative officer Engert buys $20,920 in stock - Investing.com UK
Enovis chief administrative officer Engert buys $20,920 in stock By Investing.com - Investing.com Nigeria
Enovis (ENOV) CAO adds 1,000 shares in $20.92 open-market buy - Stock Titan
Enovis CAO Oliver Engert acquires $25,948 in company stock - Investing.com UK
Enovis CAO Oliver Engert acquires $25,948 in company stock By Investing.com - Investing.com South Africa
Enovis (ENOV) CAO Oliver Engert adds 1,200 shares in open-market buys - Stock Titan
Is Enovis (ENOV) Using Spinamic to Quietly Redefine Its Orthopedic Innovation Playbook? - simplywall.st
A Look at Enovis Corp (ENOV) After 3.2% Gain -- GF Value $50.02 vs Price $21.80 - GuruFocus
Enovis stock hits 52-week low at 20.79 USD By Investing.com - Investing.com Nigeria
Insider Buying: Oliver Engert Acquires Shares of Enovis Corp (EN - GuruFocus
Enovis chief administrative officer Engert buys $23,000 in stock By Investing.com - Investing.com South Africa
Enovis chief administrative officer Engert buys $23,000 in stock - Investing.com
Enovis (ENOV) CAO Oliver Engert buys 1,000 shares in open market - Stock Titan
Medical Devices Specialty Stocks Q1 2026: Enovis Revenue Beat, Stock Down 12%News and Statistics - IndexBox
Spotting Winners: Enovis (NYSE:ENOV) And Medical Devices & SuppliesSpecialty Stocks In Q1 - Yahoo Finance
Assessing Enovis (ENOV) Valuation After Recent Share Price Weakness - Yahoo Finance
Enovis stock hits 52-week low at 20.79 USD - Investing.com
CD&R Appoints Former Enovis CEO Matthew Trerotola as Operating Advisor - citybiz
CD&R Engages Former Enovis CEO as Operating Advisor — CD&R | Building Businesses Building Value - CD&R
Is Enovis Corporation (ENOV) a High-Growth, Under-Valued Stock? - Insider Monkey
How The Investment Story For Enovis (ENOV) Is Evolving Without New Analyst Targets - Yahoo Finance
Is Enovis (ENOV) Using Spinamic To Quietly Redefine Its Orthopedics Innovation Edge? - Yahoo Finance
Enovis Launches Spinamic Hybrid Scoliosis Brace for Pediatric Patients - geneonline.com
Enovis launches hybrid scoliosis brace in U.S. market By Investing.com - Investing.com Australia
Enovis launches hybrid scoliosis brace in U.S. market - Investing.com
Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens - The Manila Times
Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining - GlobeNewswire
Why Enovis (ENOV) Is Up 9.6% After Beating Q1 Targets And Enhancing Incentive Plan Alignment - simplywall.st
A Look At Enovis (ENOV) Valuation As Shares Rebound And Long Term Returns Lag - simplywall.st
3 Reasons ENOV is Risky and 1 Stock to Buy Instead - Yahoo Finance UK
Top Enovis (ENOV) Competitors 2026 - MarketBeat
Enovis (ENOV): Revenue Beat, Margins Expand and Full-Year Outlook Maintained - Insider Monkey
Enovis Corp at JPMorgan Healthcare Conference Transcript - GuruFocus
Enovis Corp Stock Baskets - GuruFocus
Enovis chief administrative officer buys $22,220 in company stock By Investing.com - Investing.com India
Enovis chief administrative officer buys $22,220 in company stock - Investing.com
Enovis (ENOV) Chief Administrative Officer buys 1,000 shares in open market - Stock Titan
Enovis Corp (ENOV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):